OvaScience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch OvaScience and buy or sell other stocks, ETFs, and their options commission-free!

About OVAS

Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. 

CEO
Louis J. Arcudi, III, MBA
CEOLouis J. Arcudi, III, MBA
Employees
Employees
Headquarters
Ann Arbor, Michigan
HeadquartersAnn Arbor, Michigan
Founded
2012
Founded2012
Employees
Employees

OVAS Key Statistics

Market cap
15.60M
Market cap15.60M
Price-Earnings ratio
-0.16
Price-Earnings ratio-0.16
Dividend yield
Dividend yield
Average volume
177.17K
Average volume177.17K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$12.23
52 Week high$12.23
52 Week low
$0.9411
52 Week low$0.9411

Stock Snapshot

With a market cap of 15.6M, OvaScience(OVAS) trades at $9.58. The stock has a price-to-earnings ratio of -0.16.

During the trading day, OvaScience(OVAS) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for OvaScience(OVAS) stock has reached 0, versus its average volume of 177.17K.

The stock's 52-week range extends from a low of $0.94 to a high of $12.23.

The stock's 52-week range extends from a low of $0.94 to a high of $12.23.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.